8-K current report · filed Nov 6, 2026

Nkarta, Inc. (NKTX) 8-K Current Report: November 6, 2026

Item 7.01Item EX-99.1NKTX overview

Short answer

Nkarta, Inc. (NKTX) filed an 8-K current report with the SEC on November 6, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Webcast scheduled November 9, 2026 at 8:00 a.m. Eastern Time.

Nkarta, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Webcast scheduled November 9, 2026 at 8:00 a.m. Eastern Time
  • Initial clinical data from NKX019’s Ntrust program in myositis and systemic sclerosis
  • ACR Convergence 2026 presentation creates a near-term clinical catalyst for Nkarta shares

Item EX-99.1 · Exhibit EX-99.1

  • Webcast scheduled November 9, 2026 at 8:00 a.m. ET to present initial NKX019 clinical data at ACR Convergence 2026
  • Data cover Ntrust trials in myositis and systemic sclerosis, creating a near-term clinical catalyst for NKTX shares
  • Ntrust-1 and Ntrust-2 evaluate safety and remission potential through CD19-targeted B-cell elimination
  • Trials enroll up to 12 patients per dose level per disease indication, including additional autoimmune diseases
  • NKX019 uses three-dose cycles after lymphodepletion, testing off-the-shelf CAR-NK therapy without exogenous cytokine support

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Nkarta, Inc. 8-K filings

Get the next NKTX 8-K as it lands

Follow NKTX for push alerts, or ask the research agent what this filing means.